ID   P63_RAT                 Reviewed;         680 AA.
AC   Q9JJP6; Q99JD6; Q99JD7; Q99JD8; Q99JD9; Q99JE0; Q99JE1; Q99JE2; Q99JE3;
DT   04-JAN-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   02-OCT-2024, entry version 178.
DE   RecName: Full=Tumor protein 63;
DE            Short=p63;
DE   AltName: Full=Keratinocyte transcription factor KET;
DE   AltName: Full=Transformation-related protein 63;
DE            Short=TP63;
DE   AltName: Full=Tumor protein p73-like;
DE            Short=p73L;
GN   Name=Tp63; Synonyms=Ket, P63, Tp73l, Trp63;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Tongue epithelium;
RX   PubMed=9315105; DOI=10.1038/sj.onc.1201500;
RA   Schmale H., Bamberger C.;
RT   "A novel protein with strong homology to the tumor suppressor p53.";
RL   Oncogene 15:1363-1367(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4; 5; 6; 7; 8 AND 9), FUNCTION,
RP   AND TISSUE SPECIFICITY.
RC   STRAIN=Wistar; TISSUE=Tongue;
RX   PubMed=11470269; DOI=10.1016/s0014-5793(01)02643-6;
RA   Bamberger C., Schmale H.;
RT   "Identification and tissue distribution of novel KET/p63 splice variants.";
RL   FEBS Lett. 501:121-126(2001).
CC   -!- FUNCTION: Acts as a sequence specific DNA binding transcriptional
CC       activator or repressor. The isoforms contain a varying set of
CC       transactivation and auto-regulating transactivation inhibiting domains
CC       thus showing an isoform specific activity. May be required in
CC       conjunction with TP73/p73 for initiation of p53/TP53 dependent
CC       apoptosis in response to genotoxic insults and the presence of
CC       activated oncogenes. Involved in Notch signaling by probably inducing
CC       JAG1 and JAG2. Activates RIPK4 transcription (By similarity). Plays a
CC       role in the regulation of epithelial morphogenesis. The ratio of
CC       DeltaN-type and TA*-type isoforms may govern the maintenance of
CC       epithelial stem cell compartments and regulate the initiation of
CC       epithelial stratification from the undifferentiated embryonal ectoderm.
CC       Required for limb formation from the apical ectodermal ridge. Activates
CC       transcription of the p21 promoter (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:11470269}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Isoform composition of the
CC       tetramer may determine transactivation activity. Interacts with HIPK2.
CC       Interacts with SSRP1, leading to stimulate coactivator activity.
CC       Interacts with WWP1. Interacts with PDS5A. Interacts (via activation
CC       domain) with NOC2L (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=9;
CC       Name=1; Synonyms=TA2-alpha;
CC         IsoId=Q9JJP6-1; Sequence=Displayed;
CC       Name=2; Synonyms=DeltaN-alpha;
CC         IsoId=Q9JJP6-2; Sequence=VSP_012475;
CC       Name=3; Synonyms=TA2-beta;
CC         IsoId=Q9JJP6-3; Sequence=VSP_012478;
CC       Name=4; Synonyms=DeltaN-beta;
CC         IsoId=Q9JJP6-4; Sequence=VSP_012475, VSP_012478;
CC       Name=5; Synonyms=TA2-gamma;
CC         IsoId=Q9JJP6-5; Sequence=VSP_012477;
CC       Name=6; Synonyms=DeltaN-gamma;
CC         IsoId=Q9JJP6-6; Sequence=VSP_012475, VSP_012477;
CC       Name=7; Synonyms=TA1-alpha;
CC         IsoId=Q9JJP6-7; Sequence=VSP_012476;
CC       Name=8; Synonyms=TA1-beta;
CC         IsoId=Q9JJP6-8; Sequence=VSP_012476, VSP_012478;
CC       Name=9; Synonyms=TA1-gamma;
CC         IsoId=Q9JJP6-9; Sequence=VSP_012476, VSP_012477;
CC   -!- TISSUE SPECIFICITY: Widely expressed, notably in thymus, prostate,
CC       placenta, and skeletal muscle, although the precise isoform varies
CC       according to tissue type. Progenitor cell layers of skin, breast and
CC       prostate express high levels of DeltaN-type isoforms.
CC       {ECO:0000269|PubMed:11470269, ECO:0000269|PubMed:9315105}.
CC   -!- DOMAIN: The transactivation inhibitory domain (TID) can interact with,
CC       and inhibit the activity of the N-terminal transcriptional activation
CC       domain of TA*-type isoforms. {ECO:0000250}.
CC   -!- PTM: May be sumoylated. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. Polyubiquitination involves WWP1 and leads to
CC       proteasomal degradation of this protein (By similarity). {ECO:0000250}.
CC   -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative promoter usage.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing of isoform
CC       2. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 6]: Produced by alternative splicing of isoform
CC       2. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative splicing of isoform
CC       7. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative splicing of isoform
CC       7. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y10258; CAB88216.1; -; mRNA.
DR   EMBL; AJ277446; CAC37098.1; -; mRNA.
DR   EMBL; AJ277447; CAC37099.1; -; mRNA.
DR   EMBL; AJ277448; CAC37100.1; -; mRNA.
DR   EMBL; AJ277449; CAC37101.1; -; mRNA.
DR   EMBL; AJ277450; CAC37102.1; -; mRNA.
DR   EMBL; AJ277451; CAC37103.1; -; mRNA.
DR   EMBL; AJ277452; CAC37104.1; -; mRNA.
DR   EMBL; AJ277453; CAC37105.1; -; mRNA.
DR   RefSeq; NP_001120811.1; NM_001127339.1. [Q9JJP6-3]
DR   RefSeq; NP_001120813.1; NM_001127341.1. [Q9JJP6-5]
DR   RefSeq; NP_001120814.1; NM_001127342.1. [Q9JJP6-2]
DR   RefSeq; NP_001120815.1; NM_001127343.1. [Q9JJP6-4]
DR   RefSeq; NP_001120816.1; NM_001127344.1. [Q9JJP6-6]
DR   RefSeq; NP_062094.1; NM_019221.3. [Q9JJP6-1]
DR   RefSeq; XP_008767013.1; XM_008768791.2.
DR   AlphaFoldDB; Q9JJP6; -.
DR   BMRB; Q9JJP6; -.
DR   SMR; Q9JJP6; -.
DR   STRING; 10116.ENSRNOP00000033463; -.
DR   PhosphoSitePlus; Q9JJP6; -.
DR   PaxDb; 10116-ENSRNOP00000033463; -.
DR   Ensembl; ENSRNOT00000002636.8; ENSRNOP00000002636.4; ENSRNOG00000001924.9. [Q9JJP6-2]
DR   Ensembl; ENSRNOT00000036179.6; ENSRNOP00000032308.4; ENSRNOG00000001924.9. [Q9JJP6-5]
DR   Ensembl; ENSRNOT00000067251.5; ENSRNOP00000059178.3; ENSRNOG00000001924.9. [Q9JJP6-3]
DR   Ensembl; ENSRNOT00000068116.5; ENSRNOP00000061884.4; ENSRNOG00000001924.9. [Q9JJP6-1]
DR   Ensembl; ENSRNOT00055007308; ENSRNOP00055005469; ENSRNOG00055004606. [Q9JJP6-1]
DR   Ensembl; ENSRNOT00060022543; ENSRNOP00060017865; ENSRNOG00060013209. [Q9JJP6-1]
DR   Ensembl; ENSRNOT00065005426; ENSRNOP00065003953; ENSRNOG00065003713. [Q9JJP6-1]
DR   GeneID; 246334; -.
DR   KEGG; rno:246334; -.
DR   AGR; RGD:620863; -.
DR   CTD; 8626; -.
DR   RGD; 620863; Tp63.
DR   eggNOG; ENOG502QQ48; Eukaryota.
DR   GeneTree; ENSGT00950000183153; -.
DR   HOGENOM; CLU_019621_1_1_1; -.
DR   InParanoid; Q9JJP6; -.
DR   OMA; IRMQDSE; -.
DR   OrthoDB; 2902631at2759; -.
DR   PhylomeDB; Q9JJP6; -.
DR   TreeFam; TF106101; -.
DR   Reactome; R-RNO-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   PRO; PR:Q9JJP6; -.
DR   Proteomes; UP000002494; Chromosome 11.
DR   Bgee; ENSRNOG00000001924; Expressed in esophagus and 7 other cell types or tissues.
DR   GO; GO:0000785; C:chromatin; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0005654; C:nucleoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0003682; F:chromatin binding; ISO:RGD.
DR   GO; GO:0003684; F:damaged DNA binding; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; ISO:RGD.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:RGD.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0003690; F:double-stranded DNA binding; IDA:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0097371; F:MDM2/MDM4 family protein binding; ISO:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0002039; F:p53 binding; ISO:RGD.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; ISO:RGD.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:RGD.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0043565; F:sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0050699; F:WW domain binding; ISO:RGD.
DR   GO; GO:0048646; P:anatomical structure formation involved in morphogenesis; ISO:RGD.
DR   GO; GO:0009887; P:animal organ morphogenesis; ISO:RGD.
DR   GO; GO:0090398; P:cellular senescence; ISO:RGD.
DR   GO; GO:0006338; P:chromatin remodeling; ISO:RGD.
DR   GO; GO:0060197; P:cloacal septation; ISO:RGD.
DR   GO; GO:1904888; P:cranial skeletal system development; ISO:RGD.
DR   GO; GO:0008340; P:determination of adult lifespan; ISO:RGD.
DR   GO; GO:0007499; P:ectoderm and mesoderm interaction; ISO:RGD.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; ISO:RGD.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; ISO:RGD.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; ISO:RGD.
DR   GO; GO:0009913; P:epidermal cell differentiation; ISO:RGD.
DR   GO; GO:0010481; P:epidermal cell division; ISO:RGD.
DR   GO; GO:0008544; P:epidermis development; ISO:RGD.
DR   GO; GO:0002064; P:epithelial cell development; ISO:RGD.
DR   GO; GO:0030855; P:epithelial cell differentiation; ISO:RGD.
DR   GO; GO:0001736; P:establishment of planar polarity; ISO:RGD.
DR   GO; GO:0061436; P:establishment of skin barrier; ISS:UniProtKB.
DR   GO; GO:0048807; P:female genitalia morphogenesis; ISO:RGD.
DR   GO; GO:0001942; P:hair follicle development; ISO:RGD.
DR   GO; GO:0031069; P:hair follicle morphogenesis; ISO:RGD.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; ISO:RGD.
DR   GO; GO:0030216; P:keratinocyte differentiation; ISO:RGD.
DR   GO; GO:0043616; P:keratinocyte proliferation; ISO:RGD.
DR   GO; GO:0001738; P:morphogenesis of a polarized epithelium; ISO:RGD.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0033147; P:negative regulation of intracellular estrogen receptor signaling pathway; ISO:RGD.
DR   GO; GO:0045617; P:negative regulation of keratinocyte differentiation; ISO:RGD.
DR   GO; GO:2000381; P:negative regulation of mesoderm development; ISO:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0051402; P:neuron apoptotic process; ISO:RGD.
DR   GO; GO:0007219; P:Notch signaling pathway; ISO:RGD.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; ISO:RGD.
DR   GO; GO:0007389; P:pattern specification process; ISO:RGD.
DR   GO; GO:0030859; P:polarized epithelial cell differentiation; ISO:RGD.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; ISO:RGD.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:2000271; P:positive regulation of fibroblast apoptotic process; ISO:RGD.
DR   GO; GO:0010838; P:positive regulation of keratinocyte proliferation; ISO:RGD.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; ISO:RGD.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; ISO:RGD.
DR   GO; GO:1904674; P:positive regulation of somatic stem cell population maintenance; ISO:RGD.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; ISO:RGD.
DR   GO; GO:0030850; P:prostate gland development; ISO:RGD.
DR   GO; GO:0060513; P:prostatic bud formation; ISO:RGD.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0009954; P:proximal/distal pattern formation; ISO:RGD.
DR   GO; GO:0010482; P:regulation of epidermal cell division; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0001501; P:skeletal system development; ISO:RGD.
DR   GO; GO:0098773; P:skin epidermis development; ISO:RGD.
DR   GO; GO:0043589; P:skin morphogenesis; ISO:RGD.
DR   GO; GO:0007283; P:spermatogenesis; IEP:RGD.
DR   GO; GO:0060529; P:squamous basal epithelial stem cell differentiation involved in prostate gland acinus development; ISO:RGD.
DR   GO; GO:0048863; P:stem cell differentiation; ISO:RGD.
DR   GO; GO:0072089; P:stem cell proliferation; ISO:RGD.
DR   GO; GO:0048485; P:sympathetic nervous system development; ISO:RGD.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; ISO:RGD.
DR   CDD; cd08367; P53; 1.
DR   CDD; cd09572; SAM_tumor-p63; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; p53-like tetramerisation domain; 1.
DR   Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd_sf.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR037611; Tumor-p63_SAM.
DR   PANTHER; PTHR11447; CELLULAR TUMOR ANTIGEN P53; 1.
DR   PANTHER; PTHR11447:SF8; TUMOR PROTEIN 63; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SMART; SM00454; SAM; 1.
DR   SUPFAM; SSF47719; p53 tetramerization domain; 1.
DR   SUPFAM; SSF49417; p53-like transcription factors; 1.
DR   SUPFAM; SSF47769; SAM/Pointed domain; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Activator; Alternative promoter usage; Alternative splicing; Apoptosis;
KW   Developmental protein; DNA-binding; Isopeptide bond; Metal-binding;
KW   Notch signaling pathway; Nucleus; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc.
FT   CHAIN           1..680
FT                   /note="Tumor protein 63"
FT                   /id="PRO_0000185731"
FT   DOMAIN          541..607
FT                   /note="SAM"
FT   DNA_BIND        170..362
FT                   /evidence="ECO:0000250"
FT   REGION          1..107
FT                   /note="Transcription activation"
FT                   /evidence="ECO:0000250"
FT   REGION          122..171
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          351..393
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          352..388
FT                   /note="Interaction with HIPK2"
FT                   /evidence="ECO:0000250"
FT   REGION          394..443
FT                   /note="Oligomerization"
FT                   /evidence="ECO:0000250"
FT   REGION          436..472
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          610..680
FT                   /note="Transactivation inhibition"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        122..166
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        364..389
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         244
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         247
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         308
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         312
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        676
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..108
FT                   /note="MNFETSRCATLQYCPDPYIQRFIETPSHFSWKESYYRSAMSQSTQTSEFLSP
FT                   EVFQHIWDFLEQPICSVQPIDLNFVDEPSENGATNKIEISMDCIRMQDSDLSDPMW ->
FT                   MLYLESNAQTQFSE (in isoform 2, isoform 4 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:11470269"
FT                   /id="VSP_012475"
FT   VAR_SEQ         1..21
FT                   /note="MNFETSRCATLQYCPDPYIQR -> MPSC (in isoform 7, isoform
FT                   8 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:11470269"
FT                   /id="VSP_012476"
FT   VAR_SEQ         450..680
FT                   /note="QTSMQSQSSYGNSSPPLNKMNSMNKLPSVSQLINPQQRNALTPTTMPEGMGA
FT                   NIPMMGTHMPMAGDMNGLSPTQALPPPLSMPSTSHCTPPPPYPTDCSIVSFLARLGCSS
FT                   CLDYFTTQGLTTIYQIEHYSMDDLASLKIPEQFRHAIWKGILDHRQLHDFSSPPHLLRT
FT                   PSGASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMDSRRNKQQRIKEE
FT                   GE -> HLLSACFRNELVESRREAPTQSDVFFRHSNPPNHSVYP (in isoform 5,
FT                   isoform 6 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:11470269"
FT                   /id="VSP_012477"
FT   VAR_SEQ         551..680
FT                   /note="SFLARLGCSSCLDYFTTQGLTTIYQIEHYSMDDLASLKIPEQFRHAIWKGIL
FT                   DHRQLHDFSSPPHLLRTPSGASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDF
FT                   NFDMDSRRNKQQRIKEEGE -> RIWQV (in isoform 3, isoform 4 and
FT                   isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:11470269"
FT                   /id="VSP_012478"
SQ   SEQUENCE   680 AA;  76760 MW;  AC45DABB88F61400 CRC64;
     MNFETSRCAT LQYCPDPYIQ RFIETPSHFS WKESYYRSAM SQSTQTSEFL SPEVFQHIWD
     FLEQPICSVQ PIDLNFVDEP SENGATNKIE ISMDCIRMQD SDLSDPMWPQ YTNLGLLNGM
     DQQIQNGSSS TSPYNTDHAQ NSVTAPSPYA QPSSTFDALS PSPAIPSNTD YPGPHSFDVS
     FQQSSTAKSA TWTYSTELKK LYCQIAKTCP IQIKVMTPPP QGAVIRAMPV YKKAEHVTEV
     VKRCPNHELS REFNEGQIAP PSHLIRVEGN SHAQYVEDPI TGRQSVLVPY EPPQVGTEFT
     TVLYNFMCNS SCVGGMNRRP ILIIVTLETR DGQVLGRRCF EARICACPGR DRKADEDSIR
     KQQVSDSAKN GDGTKRPFRQ NTHGIQMTSI KKRRSPDDEL LYLPVRGRET YEMLLKIKES
     LELMQYLPQH TIETYRQQQQ QQHQHLLQKQ TSMQSQSSYG NSSPPLNKMN SMNKLPSVSQ
     LINPQQRNAL TPTTMPEGMG ANIPMMGTHM PMAGDMNGLS PTQALPPPLS MPSTSHCTPP
     PPYPTDCSIV SFLARLGCSS CLDYFTTQGL TTIYQIEHYS MDDLASLKIP EQFRHAIWKG
     ILDHRQLHDF SSPPHLLRTP SGASTVSVGS SETRGERVID AVRFTLRQTI SFPPRDEWND
     FNFDMDSRRN KQQRIKEEGE
//
